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BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination.
Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer
and BRCA1 deﬁcient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase
(PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway
is of extreme importance for further understanding cancer development and therapeutic
vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and reg-
ulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a
key role in homologous recombination by stimulating end resection at double-strand breaks.
EDC4 deﬁciency leads to genome instability and hypersensitivity to DNA interstrand cross-
linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in
BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer sus-
ceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA
repair whose inactivation phenocopies BRCA1 deﬁciency.
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The human genome is constantly attacked by endogenousand exogenous genotoxic agents, which leads to genomeinstability, cancer development, and aging1. Cells coun-
teract mutagenic insults through a complex DNA damage
response network2. The biomedical relevance of genome main-
tenance is illustrated by the severe clinical consequences of
mutations in DNA repair genes1. Genes involved in homologous
recombination (HR) repair pathway such as BRCA1, BRCA2, and
PALB2 are an important example. Mutations in these genes cause
familial breast cancer and the cancer-prone disease Fanconi
anemia (FA) in monoallelic and biallelic carriers, respectively3.
Furthermore, the proteins encoded by many of these genes are
crucial for the modulation of the response of cancer cells to
chemotherapeutics, including cisplatin and poly (ADP-ribose)
polymerase (PARP) inhibitors4. Therefore, the identiﬁcation of
additional components of this DNA repair pathway is of utmost
biomedical importance. Here we observe that EDC4, besides its
known role in processing-bodies (P-bodies), interacts with
BRCA1 and is involved in HR-mediated DNA repair by reg-
ulating its end-resection step and that germline mutations in
EDC4 may confer increased risk of breast cancer. Taking together
our results suggest that EDC4 is a functional phenocopy of
BRCA1 that could be targeted in cancer therapeutics.
Results
EDC4 interacts with TOPBP1 and associates with BRCA1.
TOPBP1 is required for HR repair5, 6 and interacts with BRCA1
and BRIP1 in response to DNA damage7. To uncover novel
proteins potentially involved in DNA repair and cancer predis-
position, we screened for TOPBP1 interactors using the yeast
two-hybrid system. Seven TOPBP1 baits were deﬁned based on
Pfam-predicted domains and PONDR-predicted disordered
regions8, which covered the complete protein sequence. A central
putative disordered region in TOPBP1 (amino acids 643–836)
used as a bait identiﬁed interactions with the enhancer of mRNA
decapping protein 4, EDC4 (NCBI reference sequence:
NP_055144.3; aliases: GE1, HEDLS RCD8; Fig. 1a). Notably,
EDC4 was previously found to be post-translationally modiﬁed in
response to DNA damage in proteomic studies9, 10. Four inde-
pendent preys supported the physical TOPBP1–EDC4 interaction
which was further conﬁrmed by endogenous co-
immunoprecipitation assays (Fig. 1b) and by co-afﬁnity pur-
iﬁcation assays (Fig. 1c, d).
EDC4 is known to function in the mRNA P-bodies within the
cytoplasm11. However, western blot analyses of cellular sub-
fractions (Fig. 1e) and confocal microscopy using green
ﬂuorescent protein (GFP)-tagged EDC4 (see below) demon-
strated that it is also located in the nucleus and binds to
chromatin. Nucleoplasm localization is also supported by
independent studies12. EDC4 contains a WD40-repeat domain
in its N-terminal region. This type of domain is involved in the
coordination of multi-protein complex assembly, and therefore,
we hypothesized that EDC4 can interact with other TOPBP1
partners. Accordingly, we found that BRCA1 co-
immunoprecipitates with BRIP1, as expected, and with EDC4
(Fig. 1f). These results suggest that EDC4 binds with BRCA1,
BRIP1, and TOPBP1 in a nuclear complex.
EDC4 is involved in DNA damage response. Cells deﬁcient in
downstream components of the FA/BRCA signaling pathway,
such as BRCA1 and BRIP1, are hypersensitive to DNA inter-
strand cross-linking (ICL) drugs, including mitomycin C (MMC)
or diepoxybutane (DEB). To investigate whether EDC4 is simi-
larly involved in genome maintenance, we depleted EDC4 in
HeLa cells by RNA interference (RNAi), using three independent
small interfering RNAs (siRNA) that reached depletion levels of
89–96% (Fig. 2a). EDC4 depletion rendered HeLa cells hyper-
sensitive to ICL drugs in terms of cell survival (Fig. 2b), MMC-
induced G2/M cell cycle arrest (Supplementary Fig. 1a), and
DEB-induced chromosome fragility, especially chromatid-type
aberrations and chromatid-type exchanges (Fig. 2c and Supple-
mentary Fig. 1b), whereas FANCD2 monoubiquitination in
response to MMC-induced stalled replication forks was not
affected (Supplementary Fig. 1c, d). To corroborate these ﬁnd-
ings, we used CRISPR/Cas9-mediated assays to completely
abrogate EDC4 expression (i.e., knockout (KO)) in
HEK293T cells (Supplementary Fig. 2a–c). Cell survival experi-
ments showed that complete loss of EDC4 leads to hypersensi-
tivity to DEB (Fig. 2d), exacerbated DEB-induced G2/M cell cycle
arrest, and DEB-induced chromosome fragility, determined by
the ﬂow cytometric micronucleus (MN) assay (Supplementary
Fig. 2d, e). Therefore, depletion of EDC4 results in DNA damage
sensitivity, phenocopying deﬁciencies of downstream FA/BRCA
pathway components. Next, similarly to BRCA113 and BRIP114
relocation to DNA double-strand breaks (DSBs), GFP-tagged
EDC4 was found to be quickly (<5 s) allocated to DSB in vivo, as
observed in laser micro-irradiation confocal microscopy experi-
ments in U2OS cells (Fig. 3b), which is consistent with the
nuclear function of EDC4 in DNA damage response in addition
to its role at the cytoplasmic P-bodies.
Moreover, it is reported that EDC4 is post-translational
modiﬁed by ubiquitination in lysines 514 and 1157 and by
phosphorylation in serine 741 in response to DNA damage10
(Supplementary Fig. 6a). We produced mutations of these
residues (Supplementary Fig. 6b) and we observed that cell lines
with mutations K514R and K1157R in EDC4 are sensitive to DEB
agent and this treatment induced chromosome fragility (increase
in MN frequency) and G2 arrest (Supplementary Fig. 6c–e), while
the S741A mutant does not show DEB sensitivity (Supplementary
Fig. 6c). These results indicate that the ubiquitination of EDC4 in
lysine K514 and K1157 is crucial for DNA damage resistance.
Independent roles of EDC4 in mRNA decapping and DNA
repair. Since EDC4 involvement in mRNA decapping and
maintenance of genome integrity occurs in different cellular
compartments, and as a part of different multiprotein complexes,
we hypothesized that these roles are functionally independent.
Initially, we used RNAi (Supplementary Fig. 1e) to deplete DCP1a
(decapping protein 1a), a physical interactor of EDC4 with an
essential role in P-body formation and mRNA decapping15.
Depletion of EDC4 or BRCA1, but not DCP1a, resulted in MMC
hypersensitivity (Fig. 3c) and MMC-induced cell cycle G2/M
arrest (Fig. 3d and Supplementary Fig. 8), indicating that the lack-
of-function P-bodies does not lead to DNA repair deﬁciency. As
the C-terminal part of EDC4 is essential for the formation of P-
bodies16, we next generated a series of EDC4 deletion mutants
(Fig. 3e), selected single-cell clones expressing physiological levels
of the truncated proteins (Supplementary Fig. 2f), and studied
their proﬁciency in DNA damage sensitivity (Fig. 3f) and P-body
formation (Fig. 3g). GFP-tagged EDC4 with a C-terminal deletion
(Δ6) does not form P-bodies, but maintains its repair function as
it genetically complements DEB hypersensitivity of EDC4 KO
HEK293T cells (Fig. 3f, g). In contrast, EDC4 with deleted WD40
domain (Δ2) forms P-bodies but is not functional in DNA repair
(Fig. 3f, g). Therefore, these separation-of-function deletion
mutants provide further functional evidence that the dual roles of
EDC4 are mechanistically independent.
EDC4 regulates HR-mediated repair and works with BRCA1.
Given the association of EDC4 with the TOPBP1-BRCA1-BRIP1
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complex, we next assessed the involvement of EDC4 in HR-
mediated repair. An in vivo HR assay was performed in U2OS
cells by detecting HR-mediated restoration of an incomplete GFP
expression cassette inserted in the genome17 in the presence or
absence of BRCA1, BRCA2, or EDC4. Control cells with intact
HR repair pathway exhibited efﬁcient functional GFP expression,
while, as expected, BRCA1 and BRCA2 depletion by RNAi
(Supplementary Fig. 3a) strongly abolished HR-mediated repair
(Fig. 4a, b). Notably, EDC4 depletion resulted in a highly sig-
niﬁcant reduction in the percentage of ﬂuorescent cells (Fig. 4a,
b), indicating that EDC4 also participates in HR-mediated repair.
Since EDC4 interacts with BRCA1, and BRCA1 mediates DNA
end resection at DSB, promoting error-free HR-mediated
repair18, we investigated whether EDC4 also regulates this
process. Thus, reduced end-resection tracks were observed in
EDC4 KO cells as measured by the single-molecule analysis of
resection tracks (SMART) assay (Fig. 4c). Additionally, reduced
formation of replication protein A (RPA) foci in EDC4-depleted
cells was observed (Fig. 4d and Supplementary Fig. 3b). More-
over, since BRCA119 and BRCA220 are required for downstream
loading of the RAD51 recombinase, we investigated MMC-
induced formation of RAD51 foci in the absence of EDC4. The
results demonstrated that EDC4 is also required for the formation
of these foci (Fig. 4e and Supplementary Fig. 3b). Finally, we
investigated whether EDC4-depleted cells are hypersensitive to
PARP inhibition, another hallmark of HR deﬁciency21, 22. As
shown in Fig. 4f and Supplementary Fig. 3c, EDC4 depletion
renders HeLa cells hypersensitive to the PARP inhibitor veliparib.
Considering the fact that EDC4 and BRCA1 share common
phenotypes, we studied the possibility that EDC4 and BRCA1
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Fig. 1 EDC4 interacts and with the BRCA1-BRIP1-TOPBP1 complex. a Diagram showing the region of TOPBP1 used as bait for the Y2H screen and the
different cDNAs from EDC4 captured. b Immunoblots showing that endogenous EDC4 interacts with TOPBP1 in HeLa cells. EDC4 was immunoprecipitated
and analyzed by immunoblotting with indicated antibodies. c Immunoblots showing that exogenous EDC4 interacts with exogenous TOPBP1 in HeLa cells.
EDC4 was immunoprecipitated from HeLa cells expressing both tagged EDC4 and TOPBP1 and analyzed by immunoblotting with indicated antibodies. d
Immunoblots showing that exogenous TOPBP1 interacts with exogenous EDC4 in HeLa cells. TOPBP1 was immunoprecipitated from HeLa cells expressing
both tagged EDC4 and TOPBP1 and analyzed by immunoblotting with indicated antibodies. e Cellular fractionation of HeLa cells shows that EDC4 is not
only a cytoplasmatic protein but also present at the nucleus and the chromatin. f Immunoblots showing that endogenous EDC4 interacts with BRCA1 and
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work in the same pathway. We analyzed the effect of the
simultaneous inhibition of EDC4 and BRCA1 in terms of DEB
sensitivity and HR repair efﬁciency. Depletion of EDC4 and
BRCA1 renders HeLa cells sensitive to MMC treatment in a
similar way to the individual inhibition of EDC4 or BRCA1
(Fig. 4g and Supplementary Fig. 3d). We previously established
that EDC4 shows a mild impairment in HR efﬁciency compared
to BRCA1 (Fig. 4b). In this scenario, the inhibition of BRCA1 in
cells inhibited for EDC4 shows impairment in repair similar to
the sole inhibition of BRCA1 (Fig. 4h and Supplementary Fig. 3e).
Collectively, these data indicate that loss of EDC4 phenocopies
BRCA1 deﬁciency, both being involved in the same pathway of
genome maintenance by stimulating end resection at DSBs to
promote error-free HR-mediated repair.
Germline EDC4 mutations in breast cancer patients. Several
downstream components of the FA/BRCA pathway have been
associated with breast and/or ovarian cancer risk by high or
moderate penetrance mutations3. Given the functional interac-
tion of EDC4 with FA/BRCA components in HR-mediated
repair, we investigated whether EDC4 is also mutated in breast
cancer cases. We initially sequenced the corresponding genomic
coding region, comprising all exons and exon–intron boundaries,
in blood DNA samples from 300 Spanish breast cancer index
cases that fulﬁlled one of the criteria suggestive of hereditary
breast and ovarian cancer (HBOC) syndrome, but were negative
for pathogenic mutations in BRCA1 or BRCA2 genes (see
Methods). Targeted pooled DNA ampliﬁcation followed by next-
generation sequencing was used for mutation screening as pre-
viously described23, 24. After excluding common genetic variants,
the analysis revealed ﬁve (1.67%) rare missense variants that were
all conﬁrmed by Sanger sequencing: c.125G>A, p.G42E;
c.829A>C, p.S277R; c.1083C>A, p.D361E; c.1418G>A, p.R471Q;
and c.1429G>A, p.V477M. Pedigrees are shown in Fig. 5a. These
variants were present in 2 out of 736 (0.27%) Spanish controls
(unrelated individuals not affected of neoplasms), according to
the CIBERER Spanish Variant Server (odds ratio (OR)= 6,1, p=
0.024, Fisher’s exact test). All variants were predicted to be
deleterious by PolyPhen-2 HumVar (p.G42E, p.D361E, p.R471Q,
and p.V477M) and/or CADD (p.S277R, p.R471Q, and p.V477M;
Phred-like scores >20) algorithms. In addition, all variants were
found to be clustered inside or near the functionally important
WD40 domain of EDC4 (Fig. 5b) and in regions highly conserved
in evolution (Supplementary Fig. 4). Inspection of the ExAc
database that includes approximately 120,000 alleles did not
reveal three of the above variants (G42E, S277R, and R471Q), and
D361E and V477M were found 1 and 81 (2 homozygous) times,
respectively. Thus, the ExAc frequency of EDC4 variants pre-
viously detected in breast cancer cases was of 0.14%, which is
lower than the CIBERER Spanish dataset. Noticeably, the ExAc
study identiﬁed EDC4 as an extremely intolerant gene to loss-of-
function mutations25. In our study, evaluation of related
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individuals was limited and did not show co-segregation among
the available affected relatives (Fig. 5a). However, analysis of a
breast tumor in a V477M carrier showed loss of heterozygosity
(Fig. 5a).
Subsequently, we investigated whether the identiﬁed rare
missense variants were deleterious by disrupting the newly
depicted EDC4 function in DNA damage repair. Thus, all ﬁve
missense changes were introduced in an EDC4 cDNA by site-
directed mutagenesis in a lentiviral vector, subsequently trans-
duced into EDC4 KO cells, and evaluated in cultures derived from
single-cell clones expressing physiological levels of each mutant
EDC4 (Supplementary Fig. 5a). Importantly, none of the mutants
complemented ICL-induced hypersensitivity (Fig. 5c), cell cycle
arrest (Fig. 5d), or chromosome fragility (Fig. 5e) of EDC4 KO
cells, indicating that all mutations found in breast cancer patients
disrupt the function of EDC4 in DNA repair. We then generated
GFP fusions of the patient-derived missense mutations and
observed that they do not impair P-body formation (Supplemen-
tary Fig. 5b).
Given these results, we further explored data from whole-
exome sequences of 50 Italian and 77 Spanish BRCA1/2-
mutation-negative familial breast cancer cases and found an
additional rare missense variant, c.440A>G p.Y147C in an Italian
woman. Again, this variant was not reported in ExAc, it is
predicted to be deleterious according to PolyPhen-2 and,
furthermore, corresponds to a highly conserved residue within
the WD40 domain (Supplementary Fig. 4). We genotyped this
variant and found no carriers in 66 additional BRCA1/2-
mutation-negative cases and 702 healthy controls (female blood
donors) from Italy, which is compatible with the hypothesis that
the Y147C is a rare deleterious mutation. Unfortunately, the
original breast cancer mutation carrier died, and no additional
studies of the family members were possible. Finally, several
breast cancer susceptibility genes with a role in HR-mediated
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repair are found to be mutated in FA patients. To investigate
whether EDC4 is also mutated in FA, we studied DNA or cell
lines from 17 FA patients with normal FANCD2 ubiquitination
and without mutations in any of the 22 known FA genes26. We
did not ﬁnd EDC4 mutations in 15 patients’ DNAs or lack of
EDC4 expression in 12 FA cell lines (Supplementary Table 2 and
Supplementary Fig. 7). While additional genetic analysis in larger
cohorts may be needed, our data suggest that rare variants in
EDC4 may inﬂuence breast cancer susceptibility but lack a
connection to FA.
Discussion
This study demonstrates that EDC4 has two independent func-
tions: decapping of mRNA at the P-bodies in the cytoplasm11,
and HR-mediated DNA damage repair in the nucleus. Critically,
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loss of EDC4 phenocopies the alteration of the FA/BRCA sig-
naling pathway and of BRCA1 loss of function and both are
involved in the same pathway. A number of functional connec-
tions between RNA metabolism and DNA repair exist, such as
transcription-coupled nucleotide excision repair or R-loop-
related prevention of genome instability27, with an important
role of several FA/BRCA pathway components28–31. It is also
known that several proteins involved in the smallRNA machinery
like DROSHA and DICER affect the recruitment of certain DNA
damage response factors like MDC1 and 53BP132, thus reinfor-
cing the idea of an interplay between DNA repair and RNA
metabolism. However, to the best of our knowledge, EDC4 is the
ﬁrst protein shown to have a dual role in DNA repair and mRNA
decapping. Given the dual role of EDC4, it would be interesting to
investigate whether EDC4 plays a role in homology-directed
repair using RNA as a template for DSB repair in a way similar to
Rad5233. Our results indicate that all mutations identiﬁed in
breast cancer cases are inside or near the WD40 domain of EDC4
at the N terminus of the protein. Supporting the importance of an
intact WD40 domain, large deletions involving all or part of the
WD40 domain speciﬁcally disrupted the function of EDC4 in
DNA repair (Fig. 3e, f), indicating that this is one of the most
relevant regions for EDC4 functions in genome maintenance and,
likely, breast cancer protection. However, the region 1097–1265
contained in the C-terminal deletion 5 (Δ5) also has a role in
DNA damage resistance (Fig. 3e, f). Corroborating the need of
both the N terminal and C terminal for DNA repair is the fact
that the Δ4 deletion is able to rescue the DNA damage sensitivity
of EDC4 deﬁciency (Fig. 3e, f).
Consistent with a function in DNA repair, EDC4 was reported
to be post-translationally modiﬁed by phosphorylation (S741) or
ubiquitination (K514 and K1157) in response to DNA damage in
proteomic screens9, 10. We produced mutations of these three
residues (S741A, K514R, and K1157R) and detected that K514
and K1157, but not S741, are essential for EDC4 functions in
DNA damage resistance (Supplementary Fig. 6c). In accordance
with these results, our battery of EDC4 deletion mutants indicated
that the regions comprising the ubiquitination target K514 (Δ3)
or K1157 (Δ5), but not the phosphorylation target S741 (Δ4), are
crucial for DNA damage resistance (Fig. 3e, f). We then generated
GFP fusions of these ubiquitination mutants and observed that
they do not impair P-body formation (Supplementary Fig. 5b).
Study of the role of ubiquitination in EDC4 regulation and
identiﬁcation of the responsible ubiquitin ligase may further
decipher the role of this protein in DNA repair and its link to
cancer susceptibility. Given that EDC4 interacts with BRCA1, it is
probably a member of at least one of the multiple BRCA1-
containing protein complexes: BRCA1-A, BRCA1-B, BRCA1-C,
BRCA1/PALB2/BRCA2, and the BRCA1/BARD1 heterodimer34.
Each of these complexes has different functions related to DNA
repair and cell cycle checkpoint activation and some of these
complexes have antagonistic functions. BRCA1-B and BRCA1-C
are known to promote DSB end resection18, thus promoting HR,
but BRCA1-A limits it resulting in a reduction in HR repair35.
Our present results indicate that EDC4 mutation carriers are
more frequent in breast cancer cases than in controls, and,
therefore, we propose to include EDC4 in larger sequencing
studies. In parallel, given the role of EDC4 in HR repair and the
hypersensitivity of EDC4-depleted cell lines to PARP inhibition
(Fig. 4f), our results suggest a therapeutic option for the treatment
of EDC4-mutated breast cancers by synthetic lethality. It remains
to be determined the involvement of this gene/protein in different
carcinogenic processes in which mutations of FA/BRCA DNA
repair genes are found relatively frequent, including ovarian,
pancreatic, and metastatic prostate cancer4, 36. Interestingly,
EDC4 has also been identiﬁed as frequently mutated in metastatic
breast cancer, in parallel to PALB2 and other genes37. Moreover,
whole-exome sequencing data from 412 high-grade serous ovar-
ian cancer patients from The Cancer Genome Atlas Project
identiﬁed two cases with germline truncating mutations in the N-
terminal region of EDC4 (c.508_509delAC and c.689_690delAC)
38. Therefore, independent observations further suggest a role for
altered EDC4 function in cancer development and/or progression.
In conclusion, our study demonstrates that EDC4 functionally
phenocopies BRCA1, playing a role in HR-mediated DNA repair
by regulation of end resection, and that germline mutations in
EDC4 may confer risk of breast cancer. Further studies are
required to determine its role as tumor suppressor and its
potential use as molecular target in cancer therapeutics.
Methods
Immunoprecipitation. HeLa cells seeded in 15 cm diameter petri dishes were
trypsinized and recovered. Cell pellet was washed twice with cold phosphate-
buffered saline (PBS) and cells were lysed with NTEN buffer (NP-40 0.5%, Tris 20
mM, pH 7.4, NaCl 150 mM, EDTA 1mM, pH 8, and benzonase) for 1 h at 4 °C in
rotation. Cell extracts were centrifuged at 2900 × g at 4 °C for 10 min and the
supernatant was recovered. Protein extracts were precleared for 1 h at 4 °C in
rotation using magnetic beads (Protein G Mag Sepharose Xtra, 28-9670-66 GE
Healthcare) and unspeciﬁc IgG in a proportion of 1 µg of antibody per 1 mg of
protein extract, followed with a second preclearing step using only magnetic beads
for 1 h at 4 °C in rotation. After that, protein extracts were separated in tubes and
incubated with speciﬁc and unspeciﬁc antibodies and magnetic beads overnight at
4 °C in rotation. The beads were washed four times with NTEN buffer and the
proteins were recovered with Laemmli buffer and analyzed by western blot.
Cell fractionation. Cells were harvested and washed with PBS once. The cellular
pellet was then resuspended in buffer A (0.1 Triton X-100, HEPES 10 mM, pH 7.9,
Fig. 4 EDC4 is involved in homologous recombination repair and works in the same pathway as BRCA1. a %GFP+ cells after I-SceI expression in siRNA-
silenced Mock, BRCA1, BRCA2, and EDC4 U2OS-DR-GFP cells. b Quantiﬁcation of the HR proﬁciency of BRCA1, BRCA2, and EDC4 siRNA-silenced U2OS-
DR-GFP cells. Data represent results from three experiments. Error bars indicate mean ± s.d. Means were statistically compared using the two-tailed
Student’s t test. c Results of three SMART experiments in HEK293T cells. A signiﬁcant reduction in resection track length is observed in EDC4−/−, but not
in genetically complemented EDC4−/− cells. Data shown represent results from three experiments. Error bars indicate mean ± s.d. Statistical analysis was
the Mann–whitney test. d EDC4 is required for normal RPA32 foci formation after 4 h MMC (500 ng/mL) treatment in HeLa cells. Data shown represent
results from three experiments. Error bars indicate mean ± s.d. e EDC4 is required for normal loading of RAD51 onto DSBs after 4 h MMC (500 ng/mL)
treatment in HeLa cells. Data shown represent results from at least two experiments. Error bars indicate mean ± s.d. Means were statistically compared
using the two-tailed Student’s t test. f EDC4 depletion renders HeLa cells hypersensitive to Veliparib after a 3-day treatment. Data shown represent results
from three experiments. Error bars indicate mean ± s.d. Means were statistically compared to the Mock using two-tailed Student’s t test: siBRCA2 (p=
0.0124; p= 0.0023; p < 0.0001; p= 0.0815), siEDC4 (p= 0.8183; p= 0.3206; p < 0.0001; p= 0.2856). g Simultaneous inhibition of BRCA1 and EDC4 in
HeLa cells behave similarly to the single gene inhibition after DEB treatment. Data shown represent results from three experiments. Error bars indicate
mean ± s.d. Means were statistically compared to the Mock using two-tailed Student’s t test: siEDC4 (p= 0.0181; p= 0.0231), siBRCA1 (p= 0.0158; p=
0.0188), and siBRCA1-siEDC4 (p= 0.0423; p= 0.0341). h Quantiﬁcation of the remaining HR repair of BRCA1, EDC4, and BRCA1/EDC4 siRNA-silenced
U2OS-DR-GFP cells. Data shown represent results from at least two experiments. Error bars indicate mean ± s.d
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Fig. 5 Rare EDC4 germline variants identiﬁed in breast cancer patients are functionally deleterious. a Pedigrees of the ﬁve breast cancer families with EDC4
mutations (based on NP_055144). The probands are indicated by arrows, and slashed symbols denote deceased individuals. The ages at diagnosis and/or
death are included when known. Individuals genotyped for mutations are marked either as carriers (+) or non-carriers (−). Additional clinical annotations
are depicted as shown in the inset. b Diagram showing that all the residues mutated in BRCA1/2-mutation-negative patients cluster inside or close to the
WD40 domain of EDC4. c Functional studies of mutations found in patients shown in a. All EDC4 mutants fail to revert the DEB sensitivity phenotype of
HEK293T EDC4−/− cells. Graph shows survival after DEB treatment of ﬁve EDC4mutants generated in HEK293T cells. Data shown represent results from
at least two combined independent experiments. Error bars indicate mean ± s.d. Means were statistically compared using the two-tailed Student’s t test:
EDC4−/− (p= 0.000; p= 0.000), EDC4 corrected (p= 0.760; p= 0.748), G42E (p= 0.002; p= 0.005), S277R (p= 0.024; p= 0.011), D361E (p=
0.001; p= 0.001), R471Q (p= 0.010; p= 0.017), and V477M (p= 0.000; p= 0.000). d HEK293T EDC4−/− cells expressing the mutants show
increased G2/M block induced by DEB treatment. e HEK293T EDC4−/− cells expressing the mutants show DEB-induced chromosome fragility as shown
with the ﬂow cytometric MN assay. Data shown in d, e represent results from at least three combined independent experiments. Error bars indicate mean
± s.d. Means were statistically compared using one-way analysis of variance (ANOVA) followed by a Dunnett’s multiple comparison test
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03433-3
8 NATURE COMMUNICATIONS |  (2018) 9:967 | DOI: 10.1038/s41467-018-03433-3 | www.nature.com/naturecommunications
KCl 10 mM, MgCl2 1.5 mM, sucrose 0.34 M, glycerol 10%, DTT (dithiothreitol) 1
mM) and left 8 min in ice. Suspension was then centrifuged 5 min at 1300 × g at 4 °
C. The supernatant, containing the cytoplasmic fraction, was transferred to a new
tube. The nuclear pellet was washed once with buffer A and centrifuged 5 min at
1300 × g at 4 °C. The nuclear pellet was then resuspended in RIPA buffer.
Immunoblot analysis. Cells were trypsinized and then lysed for 10 min at room
temperature in RIPA lysis buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5%
deoxycholic acid, 10% NP-40, 10 mM EDTA) supplemented with protease and
phosphatase inhibitors and benzonase. Forty to eighty micrograms of total proteins
were separated on 6–8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) gel, blotted onto nitrocellulose membranes, and incubated overnight
with the appropriate primary antibody in 5% bovine serum albumin in TTBS (20
mM Tris, 0.5 M NaCl, pH 7.5, and 0.1% Tween-20). Blots were then detected with
horseradish peroxidase (HRP)-conjugated secondary antibodies. Finally, proteins
were visualized with Luminata Crescendo Western HRP substrate
(Merck Millipore) or Pierce ECL Western Blotting substrate (Thermo Scientiﬁc).
Uncropped scans of the most important blots are shown in Supplementary
Figs. 9–12.
FANCD2 monoubiquitination analysis. HeLa cells were transfected with speciﬁc
siRNA and treated with 2 mM hydroxyurea for 24 h. Protein whole cell extracts
were prepared using RIPA buffer as previously described. Forty micrograms of
total proteins were separated on 6% SDS-PAGE gel, blotted onto nitrocellulose
membrane, and incubated overnight with anti-FANCD2 primary antibody in 5%
bovine serum albumin (BSA) in TTBS (20 mM Tris, 0.5 M NaCl, pH 7.5, and 0.1%
Tween). Finally, blots were detected with anti-rabbit HRP-conjugated secondary
antibody. Both bands of FANCD2 were quantiﬁed using ImageJ program and the
result was expressed as an ub-FANCD2/nonub-FANCD2 ratio.
MMC survival and G2 arrest after siRNA-mediated inhibitions. HeLa cells were
transfected with speciﬁc siRNA. After that, cells were untreated or treated with 10
and 25 nM of MMC for 72 h, medium was discarded, and cells were trypsinized.
Cell number and cell cycle was simultaneously analyzed by cell cytometry using
Perfect-count microspheres (CYT-PCM-100, Cytognos) and propidium iodide
(Invitrogen). Results for survival were expressed in percentage related to untreated
controls. The percentage of G2 cells was calculated from the cytometer data using
the FlowJo program. When the intensity of the propidium iodide was evaluated in a
histogram, the G2 pick was selected and the percentage of cells in G2 was calcu-
lated related to the total amount of cells that were evaluated for cell cycle
distribution.
Chromosome fragility assay. Chromosome fragility test was done on the basis of
diepoxybutane-induced chromosome fragility tests, as previously described39, 40.
Brieﬂy, wild-type (WT) primary ﬁbroblast were treated with speciﬁc siRNA and
seeded in culture ﬂask. Cells were then treated with diepoxybutane (0.02 and 0.1
µg/mL) for 4 days. Four hours before ﬁxation cultures were treated with colcemid
(Gibco). Then cultures were ﬁxed in methanol:acetic acid and metaphase spreads
were prepared and stained with Giemsa using standard cytogenetic techniques.
Metaphase cytogenetic analysis was performed in a Zeiss AXIO Imager M1
microscope coupled to a computer-assisted metaphase ﬁnder (Metasystems,
Germany).
Diepoxybutane survival. HEK293T cells were seeded in 6-well plates (150,000
cells per well) and 24 h later were treated with 0.05 and 0.1 µg/mL of diepoxybutane
(Sigma) for three population doublings. After that, cells were harvested, and the cell
number was assessed using the Beckman Cell Counter. The results were expressed
as the percentage of survival relative to untreated cultures.
Cell cultures and plasmids. U2OS cells were obtained from the American Type
Culture Collection, HEK293T cells were kindly provided by Joan Seoane of Hos-
pital Vall d’Hebron (Barcelona, Spain). HeLa cells were kindly supplied by Maria
Blasco of Spanish National Cancer Research Center (CNIO) (Madrid, Spain).
U2OS-DR-GFP cells were kindly provided by Maria Jasin of Memorial Sloan
Kettering Cancer Center (New York, USA). All cell lines were tested for myco-
plasma contamination.
U2OS, HeLa, HEK293T, and stable cell line U2OS-DR-GFP were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) (Biowest, cat. no. L0104)
supplemented with 10% fetal bovine serum (Biowest, cat. no. S181B) and
plasmocin 0.1 mg/L (Invivogen, cod ant-mpt). I-SCEI-expressing plasmid pCBAS,
empty vector (pCAGGS), and GFP-expressing plasmid NZE-GFP were kindly
provided by Dr. Maria Jasin (Memorial Sloan Kettering Cancer Center, New York).
pRetroQ-GFP-EDC4-transfected U2OS cells were sorted twice (FacsJazz, BD
Biosciences) for stable transfection and selection maintained with puromycin 0.5
µg/mL. For DNA and siRNA transfection, we used Lipofectamine 2000 (cat. no.
11668) and Lipofectamine RNAiMax (cat. no. 13778), respectively, from
Invitrogen.
Laser micro-irradiation experiments. Cells were plated, stimulated with 10 µM 5-
bromo-2-deoxyuridine (BrdU) for 24 h, and before the microscopic analysis they
were pre-treated for 10 min at 37 °C with 5 µg/mL Hoescht 33342 (Life Technol-
ogies). Images were taken with an Olympus Fluoview 1000 confocal microscope.
For laser micro-irradiation studies, cells were microirradiated with 1-s pulse ﬁve
times covering the area with the 405-nm laser at full power and images taken every
3 s for up to 2 min after laser micro-irradiation.
Plasmid transfection. Cells were transfected with plasmids using Lipofectamine
2000 (Invitrogen, 11668-019) according to the manufacturer’s instructions. Brieﬂy,
a dilution of plasmid and Lipofectamine was made using OPTI-MEM I 1×
(GIBCO, cat. no. 31985-047) and then added to the cells. After 4 h, the medium
was removed and fresh complete DMEM medium was added. Cells were allowed to
grow for 48 h before analysis.
Plasmid construction. The pCMV6-EDC4-HA-HIS was purchased from OriGene
(PS100008). The fragment containing EDC4-HA-HIS was extracted by digesting
with AsiSI and PmeI and then cloned into pGK lentiviral vector modiﬁed to
contain AsiSI and PmeI target sequences. To generate the EDC4 mutant forms,
QuikChange II XL Site-Directed Mutagenesis Kit from Agilent Technologies
(200521) was used with speciﬁc primers for each mutant (Supplementary Table 1).
For generation of EDC4-Δ4 mutant, a PCR-ligation approach was used. Brieﬂy,
using speciﬁc primers (Supplementary Table 1) two fragments were ampliﬁed.
Fragments 1 and 2 corresponding to the 5′ and 3′ side, respectively, of the point of
deletion. The reverse primer from fragment 1 and the forward from fragment 2 are
overlapping. In a second PCR, both fragments are mixed and overlapping regions
work as primers for the ﬁnal ampliﬁcation generating the EDC4-Δ4 construct.
Construct was then digested with AsiSI and PmeI and ﬁnally cloned into pGK
lentiviral vector. For pRetroQ-GFP-EDC4 construct, EDC4 was obtained from
pCMV6-EDC4-HA-H6 by PvuI+PmeI digestion, blunt ended, and cloned into
SalI-digested and blunt-ended pRetroQ-AcGFP1-C1 vector (Clontech).
CRISPR-Cas9 KO generation. The CRISPR-sgRNA (single guide RNA) construct
was generated ligating the sgRNA sequence targeting the exon 5 of EDC4 (5′-
TGGTGCGGGTGATCAGCGTC-3′) onto the pX330 plasmid containing the Cas9
gene (Addgene 4223041). This target sequence was bioinformatically designed to
minimize off-target effects41. To assess the speciﬁcity of the CRISPR endonuclease
activity, a ﬂuorescent reporter construct was generated ligating the pRG2S vector
(Labomics42) with the same sgRNA sequence used previously. Brieﬂy,
HEK293T cells were transfected with both the reporter and the CRISPR constructs.
Three days after transfection, RFP+GFP+ cells were sorted using the FACSAria II
(BD Biosciences) and subsequently seeded at one cell per well in 96-well plates.
Clones were analyzed for EDC4 protein levels and those without expression of the
protein were genotyped.
Genotyping of EDC4 KO clones. Genomic DNA was extracted using DNeasy
Blood and Tissue Kit (Qiagen) following the manufacturer's instructions. The
region surrounding the designed CRISPR target site was ampliﬁed using the fol-
lowing primers 5′-TGTTCTGCTGGATGTCCCAC-3′ and 5′-TCTCCTCAGG-
GATGAAGGGG-3′. PCR ampliﬁcation products were puriﬁed using ExoSAP-IT
(Affymetrix) following the manufacturer's instructions and sequenced using Sanger
method in order to identify homozygous mutant clones.
Generation of lentiviral particles. For lentiviral particle production, the CalPhos
Mammalian Transfection Kit (Clontech, 631312) was used to transfect the fol-
lowing plasmids onto early passages of HEK293T cells: EDC4-WT or mutant
forms, the packaging plasmid (PAX), and the lentiviral VSV-G (ENV)43. Two 10-
cm petri dishes were seeded with 5 × 106 cells for each virus. Before transfection,
the culture medium was changed and 3 µL of chloroquine 100 mM were added.
Then, for each dish, 10 µg of the EDC4-WT or mutant plasmid were mixed with
6.5 µg of PAX plasmid, 3.5 µg of ENV plasmid, 87 µL of CaCl2, and 593 µL of H2O.
While gently mixing with the vortex, 700 µL of 2× HBS solution was added
dropwise. After 15 min of incubation, 1.4 mL of the solution was added to each
plate, and 24 h later, the medium was changed. The medium containing the len-
tiviral particles was collected 48 and 72 h after transfection, then ﬁltered using a
0.42 µm ﬁlter and concentrated by centrifugation at 4000 rpm for an hour using
Amicon Ultra-15 ﬁltering units (Millipore). The concentrated lentiviral particles
were kept at −80 °C. For viral infection, HEK293T EDC4−/− cells were seeded in
a 12-well plate and infected using 50 µL of lentiviral particles. Cells were allowed to
grow for 3 days before seeding them at one cell per well in 96-well plates. Clones
were selected for similar expression levels of EDC4 compared with the HEK293T
WT cell line.
HR assay. This method was previously described17. Brieﬂy, the U2OS cell line
stably transfected with one single copy of DR-GFP construct was inhibited with
speciﬁc siRNAs. Then, cells were transfected with an I-SceI endonuclease expres-
sion vector (pCBASce) or with an empty vector (pCAGGS) or with a plasmid that
expresses GFP constitutively (pNZE-GFP). After 48 h post transfection, cells were
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processed to be analyzed by ﬂow cytometry. The percentage of HR was quantiﬁed
as percentage of GFP+ cells after I-SceI transfection once they were corrected by
the efﬁciency of transfection and by cell cycle distribution.
End-resection assay. SMART was performed as described18. Brieﬂy, cells were
grown in the presence of 10 μM BrdU for 24 h. Cultures were then irradiated (10
Gy) and harvested after 1 h. Cells were embedded in low-melting agarose (Bio-
Rad), followed by DNA extraction. DNA ﬁbers were stretched on silanized cov-
erslips, and an immunoﬂuorescence was carried out to detect BrdU. Samples were
observed with a Nikon NI-E microscope, and images were taken and processed
with the NIS ELEMENTS Nikon Software. For each experiment, at least 200 DNA
ﬁbers were analyzed, and ﬁber length was measured with Adobe Photoshop CS4.
Immunoﬂuorescence and foci formation. Immunoﬂuorescence protocol was
previously described44 and performed with some modiﬁcations. Brieﬂy, cells were
seeded in coverslips. Cells were then ﬁxed with 4% paraformaldehyde and per-
meabilized with PBS containing 0.5% Triton X-100. Cells were then blocked with
PBS containing 5% BSA and 0.05% Tween-20. Coverslips were incubated with
primary antibodies and then with secondary antibodies conjugated to Alexa Fluor
488 or Alexa Fluor 568. Finally, samples were stained with DAPI (4′, 6-diamidino-
2-phenylindole). Microscopic analysis and quantiﬁcation were performed using a
Zeiss AXIO Observer ﬂuorescence microscope. When RAD51 foci formation was
analyzed, cells were treated with 500 ng/mL MMC and left growing for 5 h. Thirty
minutes before ﬁxation the cells were labeled with 10 μM of 5-ethynyl-2′-deox-
yuridine (EdU). Then, cells were subsequently ﬁxed and processed following the
manufacturer’s instructions with the Click-it EdU Alexa Fluor 488 Imaging Kit
(C10337, Invitrogen). Rad51 foci quantiﬁcation was done by analyzing 200 EdU+
cells that were classiﬁed according to the number of cells with Rad51 foci (≤ or >5
foci per cell). For RPA32 foci formation, cells were treated with 500 ng/mL MMC
for 2 h and processed as previously described. RPA32 foci quantiﬁcation was done
by analyzing 200 EdU+ cells classiﬁed according to the number of cells with
RPA32 foci (≤ or >5 foci per cell).
PARP inhibitors. HeLa cells were plated in six-well petri dishes at a density of 1 ×
105 cells per well. After 24 h they were untreated or treated with 50, 500, 5000, or
50,000 nM of Veliparib (ABT-888, Selleckchem) and kept in culture for 72 h. Cell
number was analyzed using Beckman Cell Counter. Results were expressed as a
percentage of survival compared to untreated cultures.
RNA interference. Cells were transfected with siRNA using Lipofectamine
RNAiMAX (Invitrogen cat. no. 13778-150) according to the manufacturer’s
instructions. Brieﬂy, a dilution of siRNA and Lipofectamine was made using OPTI-
MEM I 1× (GIBCO, cat. no. 31985-047) and then added to the cells. After 4 h, the
medium was removed and fresh complete DMEM medium was added. Cells were
allowed to grow for 24 h before repeating the siRNA transfection. Forty-eight hours
after the second transfection, inhibition levels were assessed using western blot. The
following siRNAs were used: Luciferase (5′-CGUACGCGGAAUACUUCGA-3′),
EDC4-1 (5′-CAUAUCACCUGCUGCAGCA-3′), EDC4-2 (5′-CAGGAAUA-
CUUGCAGCAGCUA-3′), EDC4-3 (5′-CACUGAAGGCCAGCAGACAG-3′),
FANCD2 pool (5′-CCUCGACUCAUUGUCAGUCAACUAA-3′/5′-CCAUGU-
CUGCUAAAGAGCGUUCAUU-3′/5′-GGUGAUGGAUAAGUUGUCGU-
CUAUU-3′), BRCA1 (5′-GUGGGUGUUGGACAGUGUA-3′), BRCA2 (5′-
GGAUUAUACAUAUUUCGCA-3′), and DCP1a (SMARTpool J-021242-08, GE
Healthcare).
Antibodies. The following antibodies were used: mouse anti-BRCA1 (OP92,
Calbiochem) 1:2000, rabbit anti-BRCA2 (ab123491, Abcam) 1:2000, rabbit anti-
DCP1a (ab47811, Abcam) 1:1000, rabbit anti-EDC4 (ab72408, Abcam) 1:1000,
rabbit anti-FANCA (A301-980A, Bethyl Laboratories) 1:1000, rabbit anti-FANCD2
(ab2187, Abcam) 1:2500, rabbit anti-BRIP1 (ab16608, Abcam) 1:1000, rabbit anti-
GAPDH (ab9485, Abcam) 1:1000, rabbit anti-HA tag (ab9110, Abcam) 1:1000,
mouse anti-ORC2 (ab31930, Abcam) 1:1000, rabbit anti-RAD51 (8349, Santa
Cruz) 1:250, rabbit anti-TOPBP1 (ab2402, Abcam) 1:1000, mouse anti-vinculin
(ab18058, Abcam) 1:5000, goat anti-rabbit-Alexa 568 conjugated (A11036, Mole-
cular Probes) 1:500, goat anti-rabbit-Alexa 488 conjugated (A11034, Molecular
Probes) 1:500 and goat anti-mouse-Alexa 568 conjugated (A11031, Molecular
Probes) 1:500, goat anti-rabbit IgG-HRP conjugated (A120-201P, Bethyl Labora-
tories) 1:1000, and goat anti-mouse IgG-HRP conjugated (sc-2005, Santa Cruz)
1:1000.
Patients. The 300 cases correspond to high-risk families with suspected Hereditary
Breast and Ovarian Cancer Syndrome examined under the Hereditary Cancer
Program of the Catalan Institute of Oncology (ICO) in Barcelona, Catalonia, Spain.
In all cases, all relevant ethical regulations were applied. Informed consent was
obtained from all the patients and the study was approved by the local Ethical
Board, Bellvitge Biomedical Research Institute (IDIBELL IRB Board; PR138/16).
The cases included in this study were negative for BRCA1 or BRCA2 mutations and
matched one of the following criteria: at least three ﬁrst-degree relatives affected by
breast or ovarian cancer; or at least two ﬁrst-degree female relatives affected by
breast cancer (at least one of them diagnosed before the age of 50 years); or at least
one case of female breast cancer plus at least one case of either ovarian, female
bilateral breast, or male breast cancer. Genetic counselors collected clinical and
pathological data from affected carriers.
Mutation identiﬁcation in pooled samples. Index patients were screened for new
mutations in EDC4 by using a combination of pooled samples, PCR ampliﬁcation,
and high-throughput sequencing, as previously described24. Ampliﬁcation was
performed using Phusion High-Fidelity DNA Polymerase (New England Biolabs,
Ipswich, MA, USA) and custom-designed primers. Normalized amounts of
genomic DNA were used in PCR assays to amplify selected exons. Equimolecular
amounts of each amplicon were pooled and random ligation of amplicons was
performed in order to obtain concatemers, which were fragmented and subse-
quently used for library preparation by applying a Paired-End protocol (Illumina).
Next-generation sequencing was performed on a HiSeq-2000 at the CNAG (Bar-
celona, Spain).
Flow cytometric micronuclei assay and cell cycle analysis. HEK293T WT,
FANCA−/−, EDC4−/−, EDC4 corrected, EDC4 G42E, EDC4 S277R, EDC4
D361E, EDC4 R471Q, EDC4 V477M, EDC4 K514R, and EDC4 K1157R cell lines
were treated with 0.05 µg/mL diepoxybutane for at least one cell division in culture.
Cells were processed by ﬂow cytometry following the procedure previously
described45. Brieﬂy, cells were stained with ethidium monoazide and subsequently
lysed and stained with Sytox green. Samples were kept at 4 °C until ﬂow cytometry
acquisition.
Statistics. Signiﬁcance of the functional studies was analyzed using two-tailed
Student’s t test with the exception of: Fig. 5d, e, Supplementary Fig. 2d, e, and
Supplementary Fig. 6d, e, where a one-way analysis of variance was performed
followed by a Dunnett’s multiple comparison test, and Fig. 2c and Supplementary
Fig. 1b, where a Mann–Whitney test was performed due to a lack of adjustment to
a normal distribution of the data. A p value of <0.05 was considered statistically
signiﬁcant. RPA32 and RAD51 foci evaluation was done in a blind fashion. A
Fisher’s exact test was used to compare carrier frequencies of EDC4 variants
between controls and breast cancer cases
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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